Survival analysis further corroborated these findings, demonstrating that heightened TACSTD2 expression was linked to poor overall survival (OS) and progression-free survival (PFS) in patients treated with platinum-based therapy and in all ovarian cancer patients (Figure 4K). This evidence concerns the gene TACSTD2 and ovarian carcinoma.